The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Nippon Kayaku Clinches Supreme Court Victory in Elplat Patent Suit
Japanese generic major Nippon Kayaku said on October 4 that it won an Elplat (oxaliplatin) patent infringement suit brought against it by Debiopharm International SA as Japan’s Supreme Court turned down an appeal by the Swiss drug maker on the…
To read the full story
Related Article
- Nippon Kayaku Notches Top Court Victory for Elplat Damages Suit Too
April 2, 2018
- Nippon Kayaku Prevails in Elplat Damage Suit: High Court
June 30, 2017
- Debiopharm Takes Nippon Kayaku to Supreme Court over Elplat
February 22, 2017
- Nippon Kayaku Wins Reversal in Elplat Patent Suit
December 9, 2016
- Debiopharm Wins Elplat Patent Suit against Nippon Kayaku
March 8, 2016
BUSINESS
- Alfresa’s Cell Resources Inks Partnership with Korea’s ENCell
December 25, 2025
- Aculys Rolls Out Spydia Nasal Spray in Japan
December 25, 2025
- Pharma Hails End to “Spillover” Rule, Vows to Keep Fighting Off-Year Cuts
December 25, 2025
- Cyto-Facto Expands CPC Footprint to Win Multiple Cell Therapy Contracts
December 24, 2025
- Shionogi, Salubritas Tie Up on Hair Cell Regeneration R&D for Hearing Loss
December 24, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…